Ruvalcaba-Myhre-Smith Syndrome

Ruvalcaba-Myhre-Smith syndrome is an older name for what doctors today call Bannayan–Riley–Ruvalcaba syndrome (BRRS). BRRS belongs to a family of conditions called PTEN hamartoma tumor syndrome (PHTS). People with BRRS usually have a large head size (macrocephaly), non-cancerous growths (hamartomas) such as lipomas or intestinal polyps, and in males, small dark freckles on the glans penis. The condition is generally caused by a change (pathogenic variant) in one copy of the PTEN gene and follows an autosomal dominant inheritance pattern. Nature+1

“Ruvalcaba-Myhre-Smith syndrome” is an older name for a PTEN-related overgrowth condition that doctors now group under Bannayan-Riley-Ruvalcaba syndrome (BRRS) within the PTEN Hamartoma Tumor Syndrome (PHTS) spectrum. People typically have a very large head size (macrocephaly), benign growths called hamartomas (including intestinal polyps and lipomas), and, in many males, tiny dark spots (pigmented macules) on the penis. The core genetic change usually affects the PTEN tumor-suppressor gene, which raises lifetime risks of certain cancers; treatment focuses on surveillance and managing symptoms, not on one single “curative” drug. PMC+3PubMed+3MedlinePlus+3

Doctors now use “BRRS” rather than the older eponym because research showed several once-separate syndromes actually describe one entity tied to PTEN. That is why you will see care recommendations written for PHTS/BRRS, not for “Ruvalcaba-Myhre-Smith.” This matters for families because modern guidelines for screening (for thyroid, breast, endometrium, kidney, and other organs) come from the PHTS literature. PubMed+2NCBI+2

Other names

RMSS has been recorded under several names in the medical literature. Common synonyms include Bannayan–Riley–Ruvalcaba syndrome (BRRS), Bannayan–Zonana syndrome, Riley–Smith syndrome, macrocephaly-hamartoma syndrome, and Ruvalcaba-Myhre-Smith syndrome. These names describe the same clinical picture and today are grouped under BRRS within the PTEN hamartoma tumor syndrome spectrum. Nature+1

Types

Doctors do not divide BRRS into formal subtypes. Instead, they recognize clinical patterns within the PTEN-related spectrum. One common pattern is the “classic BRRS” presentation: macrocephaly from infancy, multiple lipomas and hemangiomas, hamartomatous intestinal polyps, and (in males) pigmented macules of the glans penis. NCBI

Another pattern is gastrointestinal-predominant disease, where hamartomatous polyps and related bowel symptoms are the main features; this sits within the same PTEN-related spectrum and overlaps with other hamartoma polyposis disorders. Orpha

A third pattern is neurodevelopmental-predominant disease: very large head size with developmental delay or autism spectrum disorder in childhood—again linked to germline PTEN variants. NCBI

A fourth pattern is vascular/soft-tissue overgrowth, where people develop complex intramuscular overgrowth lesions now called PTEN hamartoma of soft tissue (PHOST) that have a distinctive MRI appearance. PMC

Finally, adults with PTEN variants may show a Cowden-like tumor-predisposition pattern (still part of PHTS), so families often span child-onset BRRS features and adult-onset Cowden features, reflecting variable expression of the same gene change. NCBI

Causes

1. A single harmful change in the PTEN gene (one copy). This is the core cause of BRRS/RMSS and establishes the diagnosis of PTEN hamartoma tumor syndrome. NCBI

2. Loss-of-function PTEN variants (nonsense or frameshift). These stop PTEN protein from working and lead to hamartomas and overgrowth. Nature

3. Missense variants in critical PTEN domains. Some single-letter changes in PTEN’s active region reduce its enzyme activity and drive the phenotype. Nature

4. Splice-site variants that disrupt how PTEN RNA is processed, lowering normal protein levels.

5. Large intragenic deletions/duplications of PTEN detected by copy-number methods (e.g., MLPA/CMA). NCBI

6. Chromosome 10q23 microdeletions that remove PTEN (sometimes also BMPR1A), producing a BRRS picture—even in mosaic form. PubMed+1

7. Autosomal dominant inheritance from an affected parent (each child has a 50% chance to inherit the variant). NCBI

8. De novo variants (a new PTEN change first appearing in the child, with no prior family history). NCBI

9. Mosaicism (the PTEN change is present in some but not all cells), which can modify how strongly features appear. PubMed

10. PTEN’s role in the PI3K-AKT-mTOR pathway. When PTEN is reduced, cell-growth signals are overactive, producing overgrowth and hamartomas. Nature

11. Germline PTEN variants associated with macrocephaly and autism—a recognized neurodevelopmental pathway in PHTS. NCBI

12. Vascular anomaly predisposition in PTEN syndromes, contributing to hemangiomas and complex overgrowth lesions (PHOST). MDPI

13. Intestinal hamartomatous polyp predisposition, tied to the underlying PTEN dysfunction in tissue growth control. Orpha

14. Lipoma formation because of altered growth signaling in fat and connective tissue. Orpha

15. Pigmented macules of the glans penis in males—considered a characteristic cutaneous expression within BRRS. NCBI

16. Thyroid involvement (nodules/goiter), part of PTEN-spectrum minor criteria and common in PHTS. NCBI

17. Renal tumor predisposition in adulthood within the broader PHTS spectrum (screening recommended from age 40). NCBI

18. Endometrial and breast risks in women—more clearly defined in PHTS/Cowden but relevant to PTEN families overall. NCBI

19. Variable expression: the same PTEN variant can look different across people and across a lifetime (childhood BRRS-like to adult Cowden-like). NCBI

20. Contiguous-gene deletions (PTEN with nearby genes such as BMPR1A) can broaden or intensify features, especially in the gut. PubMed+1

Symptoms

1. Macrocephaly (head size ≥97th percentile), often present from birth or early infancy. MedlinePlus

2. Multiple lipomas (soft, benign fatty lumps) that can appear on the trunk or limbs. Orpha

3. Hemangiomas or other vascular malformations in the skin or soft tissues. NCBI

4. Pigmented macules on the glans penis (males)—tiny dark freckles that are a classic clue. NCBI

5. Hamartomatous intestinal polyps, sometimes causing painless bleeding, anemia, or bowel discomfort. Orpha

6. Developmental delay (motor or speech) in early childhood. NCBI

7. Autism spectrum disorder traits in some children with PTEN variants and macrocephaly. NCBI

8. Hypotonia (low muscle tone) that can delay rolling, sitting, or walking. NCBI

9. Joint hyperextensibility/hypermobility and sometimes flat feet or flexible joints.

10. Thyroid nodules or goiter, sometimes in childhood. NCBI

11. Large birth weight or length in some newborns with BRRS. NCBI

12. Learning difficulties or intellectual disability (variable severity). NCBI

13. Occasional seizures, especially when brain overgrowth is present. Nature

14. Soft-tissue overgrowth lesions (PHOST) that can be painful or enlarge over time. PMC

15. Skin and mucosal findings beyond lipomas, such as small skin growths, that overlap with the PTEN spectrum. NCBI

Diagnostic tests

A) Physical exam (bedside assessments)

1. Detailed family history and three-generation pedigree to look for PHTS features in relatives (autosomal dominant pattern). NCBI

2. Head circumference measurement plotted on age-appropriate growth charts to confirm macrocephaly (≥97th percentile). NCBI

3. Targeted skin exam for lipomas, hemangiomas, and (in males) pigmented macules of the glans penis. NCBI

4. General neurologic exam to document tone, reflexes, gait, and coordination (for hypotonia or delay). NCBI

5. Abdominal and soft-tissue palpation to feel for lipomas or masses that might need imaging confirmation. Orpha

B) “Manual” clinical tools (standardized bedside screens)

6. Standard developmental screening in infancy/toddlerhood; positive screens (e.g., M-CHAT-R/F for autism at 18–24 months) prompt referral.

7. Beighton score for joint hypermobility to quantify hyperextensibility when suspected. PMC

8. PTEN clinical scoring system (Cleveland Clinic tool) used by specialists to estimate the chance of finding a PTEN variant and to guide testing. NCBI

9. Growth-and-nutrition review (weight/length/BMI trends) because overgrowth and feeding or GI symptoms can accompany BRRS. MedlinePlus

10. Focused GI symptom screen (bleeding, anemia symptoms, constipation/diarrhea) to decide on endoscopy timing. Orpha

C) Lab and pathological tests

11. Germline PTEN sequencing (next-generation sequencing/Sanger) to look for single-letter or small insertion/deletion variants and confirm diagnosis. NCBI

12. Copy-number testing for PTEN (MLPA or chromosomal microarray) to detect large deletions/duplications. NCBI

13. Chromosome 10q23 microdeletion analysis when sequencing is negative but suspicion is high—can reveal PTEN±BMPR1A deletions (constitutional or mosaic). PubMed

14. Hamartomatous polyp histology if polyps are removed, confirming the benign hamartoma pattern seen in BRRS. Orpha

15. Thyroid function tests (TSH ± free T4) to evaluate nodules/goiter and guide endocrine follow-up. NCBI

16. Multigene panels for hamartomatous polyposis (including PTEN, BMPR1A, SMAD4) where presentation overlaps and differential diagnosis is needed. NCBI

D) Electrodiagnostic tests (when clinically indicated)

17. EEG (electroencephalogram) for children with suspected seizures or episodes, especially given occasional reports in PHTS/BRRS. Nature

18. EMG/nerve conduction studies in infants or children with marked hypotonia when a neuromuscular cause is suspected; used selectively by pediatric neurologists. PMC

E) Imaging and endoscopic tests

19. Thyroid ultrasound—yearly in children and adults with PHTS to find nodules or cancer early. NCBI

20. Colonoscopy (and, if indicated, upper endoscopy) starting in adulthood (earlier if symptomatic) to detect and manage hamartomatous polyps. Renal imaging (MRI/CT or ultrasound) is also advised from age 40 in PHTS to screen for kidney tumors. Brain MRI is used when symptoms warrant (e.g., seizures, unusual neurologic signs) or to evaluate macrocephaly; soft-tissue MRI can characterize PHOST lesions. Plans are individualized by genetics and subspecialty teams. NCBI+1

Non-pharmacological treatments (therapies & other measures)

Each item lists (150-word description | purpose | mechanism) in simple English.

1) Lifelong cancer-risk surveillance plan (core of care).
A personalized surveillance plan is the most important “treatment.” It schedules regular thyroid ultrasound, breast imaging, skin checks, kidney imaging, colonoscopies, and full physical exams. The plan starts earlier if cancer occurred young in the family, and is adjusted to age and findings. The aim is to catch problems early when treatment is easier and more successful. Mechanistically, this does not change genes, but it reduces harm by finding tumors or precancerous changes at a stage where they can be removed or treated. Families revisit the plan with clinicians each year, because recommendations evolve as new research on PHTS risks arrives. NCBI+2PMC+2

2) Genetic counseling (for the individual and family).
Counselors explain test results, inheritance (autosomal dominant), and who else in the family should be offered testing. They help with the psychological side of learning about a hereditary risk and with practical steps like insurance letters and screening schedules. The goal is informed decisions and early diagnosis in relatives who carry the variant. Mechanism: counseling doesn’t change biology, but it prevents delays by guiding the right people to the right tests and follow-up at the right time. NCBI

3) Pediatric developmental therapies (physical/speech/occupational).
Early therapy can improve motor skills, speech, and social development when delays are present. The purpose is to maximize function in daily life and school. Mechanism: repetitive, structured practice helps the brain build adaptive pathways and improves strength, balance, and communication skills even when head size is large. NCBI

4) Endoscopic polyp removal (polypectomy).
If intestinal hamartomas bleed or obstruct, endoscopists can remove them through a scope without major surgery. Purpose: stop bleeding, relieve symptoms, and reduce transfusions. Mechanism: mechanical removal of the polyp solves the source of bleeding and decreases anemia risk. Nature

5) Skin/soft-tissue procedures for lipomas or hemangiomas.
Dermatology or surgery can excise painful or troublesome growths; interventional radiology can treat some vascular lesions. Purpose: improve comfort and function and reduce bleeding risk. Mechanism: excision or targeted ablation of abnormal tissue. Wikipedia

6) Thyroid nodule pathway (US-guided FNA, selective surgery).
Suspicious nodules are biopsied; proven cancers or compressive goiters get surgery. Purpose: timely cancer treatment and symptom relief. Mechanism: risk-stratified triage using ultrasound and cytology, then surgical removal if indicated. PMC

7) Breast risk-reduction strategies (screening ± prophylaxis in select cases).
Most adults follow intensive imaging; a few very high-risk cases may consider preventive surgery after specialist counseling. Purpose: lower cancer mortality. Mechanism: earlier detection via MRI/mammography; risk-reducing surgery removes tissue at risk in carefully selected scenarios. AACR Journals

8) Kidney surveillance and nephrology input.
Periodic imaging aims to catch kidney tumors early. Purpose: organ preservation by detecting small lesions. Mechanism: targeted imaging leads to earlier, less invasive treatments. PMC

9) Gynecologic assessment for abnormal bleeding.
Evaluation rules out endometrial pathology; management ranges from observation to surgery depending on findings. Purpose: prevent overlooked cancer. Mechanism: screening and diagnostic sampling identify precancer/cancer at a treatable stage. PMC

10) Nutrition care (iron and vitamin D focus).
Dietitians address iron loss from GI bleeding and bone health. Purpose: restore nutrients and energy. Mechanism: dietary optimization and supplement guidance to correct low iron or vitamin D when confirmed by labs. Office of Dietary Supplements+1

11) Constipation management (behavioral and bowel regimen).
Fiber, fluids, timed toileting, and safe laxatives can ease constipation common after GI procedures. Purpose: comfort and regularity. Mechanism: osmotic and bulk effects restore stool moisture and frequency. FDA Access Data

12) Psychological support and peer networks.
Living with lifelong screening is stressful; counseling and support groups help. Purpose: reduce anxiety and improve coping. Mechanism: cognitive and social supports enhance resilience and adherence to surveillance. National Organization for Rare Disorders

13) Activity/physiotherapy for musculoskeletal issues.
Targeted exercises help posture, core strength, and scoliosis comfort. Purpose: pain reduction and function. Mechanism: muscle conditioning and joint stabilization. ERN ITHACA

14) Sun-safe skin habits and dermatology follow-up.
Sun protection and yearly checks lower skin cancer risk in PHTS. Purpose: risk reduction and early detection. Mechanism: UV exposure reduction and visual surveillance by experts. PMC

15) Tailored school supports (IEP/504).
Educational plans accommodate learning or behavioral needs so children can thrive. Purpose: equal access to learning. Mechanism: environmental and instructional modifications. PMC

16) Preconception and pregnancy counseling.
Discuss inheritance, testing options, and maternal screening during pregnancy. Purpose: informed family planning and safe obstetric care. Mechanism: anticipatory guidance for genetic risks and surveillance schedules. NCBI

17) Specialist care coordination (“medical home”).
A named clinician coordinates endocrinology, gastroenterology, genetics, surgery, and imaging. Purpose: fewer gaps and duplicated tests. Mechanism: centralized plans aligned with PHTS guidelines. NCBI

18) Evidence-based pediatric surveillance in PHTS.
Updated recommendations outline thyroid US, neuro checks for symptoms, skin exams, and development tracking. Purpose: age-appropriate monitoring. Mechanism: structured schedules based on consensus updates. PMC

19) Clinical trials consideration.
Select centers study mTOR-pathway therapies and other options for severe manifestations; eligibility is case-specific. Purpose: access to emerging care. Mechanism: protocol-based therapy under monitoring. ClinicalTrials.gov

20) Lifestyle cancer-prevention basics.
Don’t smoke, keep a healthy weight, stay active, and limit alcohol. Purpose: lower overall cancer risk alongside genetic surveillance. Mechanism: reducing modifiable risks that interact with genetic risk. PMC

---

Drug treatments

There is no FDA-approved drug specifically for “Ruvalcaba-Myhre-Smith/BRRS/PHTS” that changes the gene or cures the syndrome. Medicines are used to treat specific problems (e.g., hemangiomas, thyroid disease, anemia, constipation). Below are 20 commonly used, evidence-anchored options, with FDA labeling sources where relevant; some uses are off-label and should only be considered by specialists.

1) Propranolol oral solution (HEMANGEOL) for infantile hemangioma
What: Liquid propranolol is FDA-approved to treat growing infantile hemangiomas that need systemic therapy. Class: non-selective beta-blocker. Dose/Time: starts around 0.6 mg/kg twice daily, titrated after 1–2 weeks; dosing and meals are specified on label. Purpose: shrink hemangiomas, reduce ulceration/bleeding. Mechanism: vasoconstriction, anti-angiogenic signaling, and reduced endothelial proliferation. Side effects: hypoglycemia (especially if fasting/ill), bradycardia, hypotension, bronchospasm; strict infant safety steps apply. Evidence: FDA label; also pediatric studies. FDA Access Data+2FDA Access Data+2

2) Sirolimus (Rapamune) for severe vascular/hamartomatous complications (off-label)
What: mTOR inhibitor sometimes tried when lesions are diffuse, bleeding, or refractory. Class: mTORC1 inhibitor. Dose/Time: transplant labels outline tablet/solution dosing; in PHTS, dosing is individualized with trough-level monitoring. Purpose: shrink or stabilize hamartomas/vascular anomalies. Mechanism: down-regulates PI3K/AKT/mTOR signaling overactive in PTEN loss. Side effects: mucositis, hyperlipidemia, cytopenias, infection risk; contraception is required. Evidence: case reports/series and early studies suggest benefit but data are limited; use only in expert centers. Nature+5FDA Access Data+5FDA Access Data+5

3) Everolimus (Afinitor) for complex lesions (off-label)
What: another mTOR inhibitor used in other genetic overgrowth syndromes; occasionally considered in PHTS complications. Class: mTOR inhibitor. Dose/Time: label dosing exists for oncology and TSC-related SEGA; off-label PHTS dosing requires specialist oversight. Purpose: potential size reduction of problematic hamartomas. Mechanism: mTOR pathway blockade. Side effects: mucositis, infections, metabolic changes. Evidence: no PHTS-specific approval; use is extrapolated and investigational. FDA Access Data+1

4) Levothyroxine for hypothyroidism
What: thyroid hormone replacement if thyroid under-functions or after thyroid surgery. Class: synthetic T4. Dose/Time: once daily, empty stomach; dose individualized to TSH/FT4 and age. Purpose: normalize thyroid levels and relieve fatigue, cold intolerance, constipation. Mechanism: replaces deficient hormone. Side effects: overtreatment causes palpitations, bone loss; undertreatment leaves symptoms. Evidence: FDA-labeled indications. FDA Access Data+1

5) IV iron (iron sucrose, Venofer) for significant iron-deficiency anemia
What: for moderate/severe anemia or intolerance of oral iron from GI blood loss due to polyps. Class: parenteral iron. Dose/Time: given IV in calculated cumulative doses. Purpose: restore iron quickly and raise hemoglobin. Mechanism: direct iron replacement for erythropoiesis. Side effects: infusion reactions, hypotension (rare). Evidence: FDA labeling for iron sucrose (condition-agnostic for IDA). FDA Access Data+1

6) Oral iron (ferric maltol or approved oral formulations) for mild anemia
What: pill-based iron therapy when tolerated and appropriate. Class: oral iron. Dose/Time: daily or alternate-day per clinician guidance. Purpose: replenish iron stores. Mechanism: improved iron absorption to correct deficiency. Side effects: GI upset, constipation. Evidence: FDA review documents for ferric maltol support efficacy in IDA (various causes). FDA Access Data

7) Polyethylene glycol 3350 (PEG) for constipation
What: osmotic laxative powder. Class: osmotic agent. Dose/Time: once daily; titrate to effect. Purpose: soften stool and ease bowel movements, especially after GI procedures. Mechanism: retains water in stool. Side effects: bloating; avoid overuse. Evidence: FDA-labeled OTC and prescription PEG products. FDA Access Data

8) Topical or procedural hemostatics (per endoscopist) for bleeding polyps
What: epinephrine injection, clips, thermal therapy. Class: procedural agents. Dose/Time: per endoscopy. Purpose: stop active bleeding. Mechanism: vasoconstriction, mechanical closure, coagulation. Evidence: standard GI practice in hamartomatous polyposis. Nature

9) Analgesics (acetaminophen first-line) for post-procedure pain
What: pain relief after polypectomy or lesion excision. Class: analgesic. Dose/Time: label-based dosing and maximums. Purpose: comfort without bleeding risk. Mechanism: central COX inhibition (acetaminophen). Side effects: hepatotoxicity with overdose. Evidence: standard analgesia guidance. Nature

10) Dermatologic wound care topicals for ulcerated hemangiomas
What: dressings, barrier creams; antibiotics only if infected. Class: supportive meds/devices. Purpose: promote healing, prevent infection. Mechanism: moisture balance and protection. Evidence: hemangioma care pathways alongside propranolol. PMC

11) Octreotide for certain GI bleeding scenarios (specialist-directed, off-label here)
What: peptide analog that reduces splanchnic blood flow and secretions; used in some GI bleeding contexts. Class: somatostatin analog. Dose/Time: subcutaneous or IV per label for approved indications; off-label decisions are specialist-only. Purpose: bridge control of bleeding in select cases. Mechanism: vasoactive and anti-secretory effects. Side effects: gallstones, glucose changes. Evidence: FDA label (for approved endocrinologic indications); GI bleeding use is off-label. FDA Access Data+1

12) Antibiotics (only when infection is present)
What: for skin or GI-related infections. Class: varies. Dose/Time: culture-guided. Purpose: treat infection and allow wounds to heal. Mechanism: pathogen eradication. Evidence: standard of care; not syndrome-specific. Nature

13) Hormonal therapy pathways after thyroid surgery
What: levothyroxine ± TSH-suppressive dosing if cancer treated, under endocrinology. Class: thyroid hormone. Purpose: replace hormone and, in cancer cases, reduce TSH stimulus. Mechanism: endocrine feedback control. Evidence: FDA-labeled levothyroxine plus oncology guidelines. FDA Access Data

14) Iron chelation (e.g., deferiprone) only for transfusion iron overload
What: if repeated transfusions cause iron overload. Class: iron chelator. Dose/Time: label-directed for overload (not for IDA). Purpose: remove excess iron. Mechanism: binds iron for excretion. Evidence: FDA documentation for chelators; rarely needed in BRRS unless transfusion-dependent. FDA Access Data

15) Proton-pump inhibitor (PPI) adjunct during acute GI bleeding
What: acid suppression when upper-GI bleeding suspected. Class: PPI. Dose/Time: per label. Purpose: stabilize clots and reduce rebleeding risk in peptic sources. Mechanism: gastric acid reduction. Evidence: GI practice standards (adjunctive). Nature

16) Antihistamines (itch relief) for skin irritation after procedures
What: short-term itch relief. Class: H1 blockers. Purpose: comfort. Mechanism: histamine receptor antagonism. Evidence: supportive care norms. Nature

17) Local anesthetics for minor procedures
What: numbing agents for polypectomy or excision sites. Class: amide anesthetics. Purpose: procedural comfort. Mechanism: sodium channel blockade. Evidence: standard procedural care. Nature

18) Antiemetics post-procedure as needed
What: ondansetron, etc., to control nausea. Class: 5-HT3 antagonists. Purpose: comfort and hydration. Mechanism: serotonin receptor blockade. Evidence: peri-procedural standards. Nature

19) Vaccinations per schedule
What: routine immunization; if on mTOR inhibitors, timing may be adjusted. Class: vaccines. Purpose: prevent infections. Mechanism: adaptive immunity. Evidence: standard immunization guidance; discuss live vaccines if immunosuppressed. FDA Access Data

20) Clinical-trial medicines (investigational)
What: selected centers test sirolimus-based or combination regimens for PHTS complications. Purpose: evaluate safety/benefit. Mechanism: pathway-targeted therapy. Evidence: registered and published early-stage studies. ClinicalTrials.gov+1

---

Dietary molecular supplements

Supplements should be guided by lab results and clinicians; they do not fix the PTEN variant but can support health.

1) Vitamin D (if low): supports bone health, especially if thyroid surgery or reduced mobility. Typical adult dosing ranges from 800–2000 IU/day, individualized to blood levels. Mechanism: improves calcium absorption and bone mineralization. Safety: avoid excess; monitor 25-OH-D to prevent toxicity. Office of Dietary Supplements

2) Iron (if iron-deficient): treats anemia from GI bleeding. Dose depends on formulation; clinicians sometimes prefer IV iron in significant anemia. Mechanism: replenishes iron for red blood cell production. Safety: avoid unnecessary iron if not deficient. Office of Dietary Supplements

3) Omega-3 fatty acids: can support cardiovascular health in adults per broader evidence; not syndrome-specific. Typical supplemental EPA/DHA doses vary (e.g., 1 g/day for triglyceride support under clinician advice). Mechanism: influences lipid metabolism and inflammation. Office of Dietary Supplements

4) Calcium (with vitamin D as indicated): supports bone strength when diet is low. Mechanism: mineral for bone matrix. Doses individualized to total daily intake. Office of Dietary Supplements

5) Probiotics (selected strains): may help antibiotic-associated diarrhea or gut comfort in some settings; choose well-studied strains. Mechanism: microbiome modulation. NCCIH+1

6) Oral rehydration/electrolyte solutions: helpful after bowel prep or bleeding episodes. Mechanism: restore fluids/electrolytes. FDA Access Data

7) Fiber supplements (psyllium or inulin): for constipation alongside diet and fluids. Mechanism: increases stool bulk and moisture. FDA Access Data

8) Multinutrient formulas during recovery: short-term if appetite is low after procedures. Mechanism: ensures macro/micronutrient coverage. Office of Dietary Supplements

9) Protein supplements when intake is poor: supports wound healing after surgeries. Mechanism: amino acids for tissue repair. Office of Dietary Supplements

10) Registered-dietitian–guided plans: not a pill but essential—optimize iron, vitamin D, calcium, and fiber from food first; use supplements to correct specific deficits. Office of Dietary Supplements+1

---

Drugs labeled immunity booster / regenerative / stem-cell

There are no FDA-approved “immunity booster,” “regenerative,” or “stem-cell drugs” for PTEN Hamartoma Tumor Syndrome/BRRS. Unregulated “stem-cell” products can be dangerous. If a clinician is considering sirolimus/everolimus, that’s targeted pathway therapy—not an “immune booster”—and is off-label here with infection risks. Safer alternatives: enroll in legit clinical trials at experienced centers when severe complications exist. FDA Access Data+2FDA Access Data+2

Surgeries (what they are and why done)

1) Endoscopic polypectomy (scope removal of polyps). Procedure removes bleeding or obstructive hamartomas without cutting the abdomen. Done to stop bleeding, prevent anemia, and reduce obstruction. Nature

2) Thyroid surgery (lobectomy/thyroidectomy) for cancer or compressive disease. Performed when biopsy shows malignancy or nodules press on airway/esophagus. Purpose: definitive cancer treatment or symptom relief. PMC

3) Soft-tissue mass excision. Done when lipomas or vascular malformations cause pain, bleeding, or movement limits. Purpose: comfort and function. Wikipedia

4) Segmental bowel resection (rare). Considered only for severe, uncontrolled bleeding/complications not manageable endoscopically. Purpose: life-saving bleeding control. Nature

5) Risk-reducing breast procedures (select adults). After intensive counseling, some high-risk adults consider surgery; most rely on enhanced imaging instead. Purpose: reduce lifetime risk. AACR Journals

---

Preventions

1. Follow a written surveillance plan and keep appointments. NCBI

2. Annual thyroid ultrasound beginning in youth per expert guidance. facingourrisk.org

3. Regular skin checks and sun protection. PMC

4. Age-appropriate breast imaging in adults at risk. AACR Journals

5. Colonoscopy schedule individualized for polyps. PMC

6. Renal imaging at suggested intervals in adults. PMC

7. Prompt evaluation of abnormal uterine bleeding. PMC

8. Manage anemia early (labs, iron plan). Nature

9. Healthy lifestyle (no smoking, active living, weight management). PMC

10. Family genetic counseling/testing to identify at-risk relatives sooner. NCBI

---

When to see doctors (red-flag moments)

See your team urgently for: new or heavy GI bleeding (black/tarry stools or bright red blood), rapidly growing neck lump or voice changes, new breast lumps, unexplained weight loss, blood in urine, severe headaches or neurologic changes, or painful enlarging skin/soft-tissue masses. These can signal complications that benefit from early diagnosis in PHTS. PMC

---

What to eat and what to avoid

Eat more:

1. Iron-rich foods (lean meats, legumes, fortified cereals) when iron is low. Office of Dietary Supplements

2. Vitamin-C-rich foods with plant iron (helps absorption). Office of Dietary Supplements

3. Calcium and vitamin D sources for bones (dairy or fortified alternatives; safe sun; dietitian-guided supplements only if needed). Office of Dietary Supplements

4. High-fiber foods (whole grains, fruits, vegetables, pulses) for bowel regularity. FDA Access Data

5. Omega-3-rich fish (e.g., salmon, sardines) weekly for general heart health. Office of Dietary Supplements

Limit/avoid:

1. Alcohol (moderation supports cancer-risk reduction). PMC
2. Smoking/tobacco (strong cancer co-risk). PMC
3. Highly processed foods with poor fiber when constipated. FDA Access Data
4. Excess supplements not guided by labs (e.g., too much vitamin D or iron can harm). Office of Dietary Supplements+1
5. Unregulated “stem-cell” or “immune booster” products marketed online. Stick to clinician-guided care. ClinicalTrials.gov

---

FAQs

1) Is Ruvalcaba-Myhre-Smith the same as BRRS?
Yes. It’s the older name for what is now called Bannayan-Riley-Ruvalcaba syndrome in the PTEN Hamartoma Tumor Syndrome family. PubMed

2) What gene is involved?
Most people have a pathogenic PTEN variant; this is confirmed by genetic testing. NCBI

3) Is there a cure?
No gene-editing cure exists today. Care focuses on surveillance and treating problems early. PMC

4) What cancers are watched for?
Breast, thyroid, kidney, endometrium, colon (varies by guideline and person). PMC

5) How early does screening start?
Thyroid ultrasound can start in childhood; adult screening begins by age 18 (or earlier depending on family history). facingourrisk.org+1

6) Do all males have penile macules?
No, but they are common and helpful clues for diagnosis. MedlinePlus

7) Can children have developmental needs?
Yes. Early therapies help motor, speech, and social skills. Nature

8) Are mTOR drugs standard?
No. Sirolimus/everolimus are off-label options for severe complications in expert hands; evidence is growing but limited. PubMed+1

9) Is propranolol really approved for hemangiomas?
Yes—HEMANGEOL is FDA-approved for infantile hemangioma requiring systemic therapy. FDA Access Data

10) Should every adult get colonoscopy?
Colonoscopy timing is individualized; many adults with PHTS/BRRS do undergo periodic colonoscopy because polyps are common. PMC

11) Will my children inherit this?
PHTS is autosomal dominant; each child has a 50% chance if a parent has the variant, though many cases are de novo. Genetic counseling helps. NCBI

12) Are special diets required?
No special “PTEN diet” exists; focus on balanced nutrition, iron and vitamin D status, and fiber for bowel regularity. Office of Dietary Supplements+1

13) What about probiotics?
Some strains can help antibiotic-associated diarrhea; benefits are strain-specific and not universal. NCCIH

14) Are head size and brain cancer linked here?
Macrocephaly is common, but routine brain imaging is symptom-driven; your team will advise if headaches or neurologic signs appear. NCBI

15) Where can I find reliable guidelines?
See GeneReviews® and consensus guidance for PTEN Hamartoma Tumor Syndrome; ask your team to tailor a plan for you. NCBI+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 17, 2025.